Genomind: Can Genetic Testing Help Find the Best Anxiety Medication?

What genetic testing can—and can’t—tell you about psychiatric medications

Choosing a medication for anxiety can be frustrating, particularly if you’ve already had an experience with a medication that didn’t work, caused difficult side effects, and left you unsure about what to try next. It’s understandable that many patients want to know whether genetic testing can make that process more precise.

Genomind is a form of pharmacogenomic testing, sometimes abbreviated PGx testing. It analyzes variations in your genes that may influence how your body processes and responds to certain medications. The information can sometimes help a psychiatrist make a more informed decision about medication selection, dosing, or how cautiously a medication should be introduced.

What it can’t do is identify one definitive “best anxiety medication” for you. Genetic testing has the potential to enhance psychiatric prescribing, and it can be very helpful—but it’s not a replacement for clinical judgment.

What Does Genomind Testing Actually Tell You?

Two people can take the same medication at the same dose and have very different experiences. One reason is that genetic differences can affect the enzymes involved in metabolizing certain medications.

This can matter because someone who metabolizes a medication unusually slowly may experience higher drug exposure at a conventional dose, while someone who metabolizes it faster than normal may have an entirely different pattern of exposure. As a result, having this information at the outset of the medication selection process can better inform the path forward: the choice of medication, starting dose, target dose, etc.

The FDA recognizes a number of gene-drug relationships for which genetic information may help inform therapeutic strategy or dosing. At the same time, the FDA also emphasizes that the strength and clinical significance of these relationships vary substantially from one medication to another.

That distinction is important. A genetic result isn't a prediction of your future. It's another piece of information.

Can Genomind Find the Best Anxiety Medication?

Not exactly, and I think it's important to be clear about that.

There isn't currently a genetic test that can reliably tell a patient, “This is the anxiety medication that will work best for you.” Even Genomind notes that pharmacogenomic testing doesn't determine a perfect medication. The results are meant to be considered alongside symptoms, previous medication experiences, family history, other medications, medical conditions, and treatment goals.

Most importantly, it’s essential that you have the correct diagnosis to begin with. A Genomind test is not diagnostic. It helps guide medication selection. If you’re not sure what you’re trying to treat, then the genetic information isn’t going to be very useful.

This is particularly relevant in psychiatry because medication response depends on much more than drug metabolism. The accuracy of the diagnosis matters. So do sleep, alcohol and substance use, medical conditions, stress, adherence, other medications, and the particular symptoms we're trying to treat.

Genetic testing can therefore help narrow uncertainty in some situations, but it doesn't eliminate uncertainty.

When Can Genetic Testing Be Most Useful?

Perhaps you've had unusually strong side effects from previous psychiatric medications. Maybe several medication trials haven't produced the expected benefit. You may have responded partially to a medication but had difficulty tolerating the dose needed for a fuller effect. In other cases, a patient simply has a complicated medication history and wants to make the next decision with as much relevant information as possible.

Testing can also be considered earlier in treatment when a patient strongly prefers having additional information and wants to find the ideal solution as quickly and efficiently as possible. Whether it's worthwhile depends on the individual situation.

The point isn't to order more data simply because the data is available. It's to determine whether the information has a reasonable chance of changing the treatment decision.

Why Interpretation Matters

The most important part of pharmacogenomic testing may not be the test itself, but how the results are interpreted.

A Genomind report contains genetic information that has to be placed in the context of an actual person. A finding that matters significantly for one medication may have little relevance to another. Some gene-drug relationships have relatively established clinical guidance, while others have less evidence supporting their use in prescribing decisions.

This is also why I don't think these reports should be treated as a list of “good medications” and “bad medications.” The FDA has specifically cautioned against relying on genetic tests to predict medication response when a particular gene-drug relationship hasn't been sufficiently established.

The report is a tool for clinical reasoning, not a substitute for it.

How I Use Genomind in My Psychiatry Practice

For patients in my practice who may benefit from pharmacogenomic testing, I can order Genomind testing and then review and interpret the results in the context of their psychiatric treatment.

The testing itself uses a cheek-swab sample. Genomind then provides a pharmacogenomic report that can be reviewed alongside your diagnosis, current and previous medications, side-effect history, treatment response, and other relevant clinical information.

Sometimes the results support what we were already considering. Sometimes they suggest that a particular medication or dose deserves additional caution. And sometimes they don't substantially change the treatment plan.

All three outcomes can be useful if the question is approached correctly.

The goal of genetic testing in psychiatry isn't to replace thoughtful prescribing with an algorithm. It's to add another source of information that may help us make a more informed decision together.

For someone who has struggled with medication side effects, unsuccessful trials, or uncertainty about what to try next, that additional information can sometimes make the treatment process feel considerably less arbitrary.